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Synthesis and DNA interaction of ethylenediamine platinum(II) 
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Departamento de Química Orgánica. Universidad de Alcalá, 28871-Alcalá de Henares (Madrid), Spain 
 
Abstract— A series of ethylenediamine platinum(II) complexes connected through semi-rigid chains of 1,2-bis(4-pyridyl)ethane to 
DNA intercalating subunits (naphthalene, anthracene or phenazine) has been synthesized, and their interactions with calf thymus 
(CT) DNA have been evaluated by viscometric titrations and equilibrium dialysis experiments. The parent ligands that contain 
anthracene or phenazine chromophores showed a monointercalative mode of DNA interaction (especially the anthracene derivative), 
with apparent association constants in the order of 104 M-1. The corresponding platinum(II) complexes bind CT DNA through 
bisintercalation, as established by the significant increase of DNA contour length inferred from viscosity measurements, and the 
association constants are in the order of 105 M-1. The naphthalene derivatives, however, exhibit a mixed mode of interaction, which 
suggests a partial contribution of both intercalation and groove binding for the ligand, and monointercalation in the case of the 
platinum(II) complex. Competition dialysis experiments carried out on the intercalative compounds have revealed a moderate 
selectivity towards GC DNA sequences for the derivatives containing the anthracene chromophore. 
 
Keywords: Platinum(II) complexes; DNA intercalants; DNA interactions. 
 
* Corresponding author. Fax: + 34 91 8854686 (A.L.); E-mail: antonio.lorente@uah.es
*Manuscript
Click here to view linked References
 2 
 
1. Introduction  
Small molecules can interact with nucleic acids in different ways: groove binding, intercalation between the 
DNA or the RNA base pairs, covalent binding, electrostatic interactions, etc.
1
 As a result of these interactions, 
both the structure and function of nucleic acids can be modified and, subsequently, many compounds that bind 
DNA have found relevant applications in therapy, e.g. as antitumor drugs.
2
 Typical DNA intercalation does not 
affect Watson-Crick base pairing, but notably distorts its regular helical conformation, unwinding the helix at the 
binding site and thus leading to an interference with the action of DNA binding enzymes, such as DNA 
topoisomerases and DNA polymerases. DNA topoisomerase interference significantly affects the degree of DNA 
unwinding, whereas interference with the polymerases may lead to inhibition of DNA extension, proofreading 
and repair. 
Among the family of compounds that can recognize and bind DNA by intercalation, DNA bisintercalants are 
interesting compounds, because they usually present higher affinity and selectivity for DNA and much slower 
dissociation kinetics than their monointercalant counterparts.
3
 However, many DNA bisintercalants containing 
flexible linkers between the intercalative subunits hardly represent an improvement in affinity or sequence 
selectivity, probably due to the existence of an auto-stacking process between the intercalating moieties.
4-5
 On the 
contrary, some natural antibiotics, such as echinomycin, display the two DNA intercalating moieties connected 
through rigid linkers, which makes them high-affinity DNA binders that resemble molecular staples for duplex 
DNA.
6-7
 
In this paper, we describe the synthesis and DNA interactions of a series of potential DNA bisintercalating 
compounds containing naphthalene, anthracene or phenazine subunits as chromophores, connected through semi-
rigid chains of 1,2-bis(4-pyridyl)ethane, and assembled through an ethylenediamineplatinum(II) moiety. 
Ethylenediamine platinum(II) complexes and other platinum(II) complexes bound to DNA intercalants have 
received much attention over the years, mainly due to their interesting DNA binding properties and, in some 
cases, relevant biological activities.
8
 Intercalants with positively charged groups attached typically bind to DNA 
with the positive charges facing the minor groove. In the case of the compounds reported in this paper, the 
connecting chains tethered to the two planar chromophores have been designed taking into account that 
pyridinium groups can favor DNA binding through interactions between the cationic nitrogens and the  
hydrogens with the phosphate backbone,
9-10
 besides the favorable interactions with adenine N-3 or with thymine 
C(2)=O. On the other hand, a platinum moiety bound to an intercalant may lead to disposition of the platinum 
moiety in the minor groove.
11
 Thus, additional interactions between amino groups in the ethylenediamine 
platinum(II) subunit and the phosphate backbone might also favor DNA binding.
12
 Furthermore, the chosen 
spacer provides sufficient solubility in aqueous solutions to study DNA-ligand interactions. Finally, as the 
distance between chromophores, as measured by CPK models, is approximately 16 Å, a DNA bisintercalation 
phenomenon for these platinum(II) complexes following the nearest neighbor-exclusion principle would be 
expected. 
 
2. Results and discussion 
2.1 Synthesis  
 
The general synthetic route for the preparation of compounds 1-3 (Scheme 1) involved the reaction of 1,2-
bis(4-pyridyl)ethane with an appropriate halogen derivative of 2-methylnaphthalene, 9-methylanthracene or 2-
methylphenazine, followed by reaction with ethylenediaminedichloroplatinum(II) to afford the metal complexes 
4-6 in 22 to 61% yield. For compounds containing phenazine (3 and 6), the precursor 2-methylphenazine was 
previously prepared following a reported procedure.
13
 This route consisted of a condensation reaction between a 
diketone, in this case a methyl orthoquinone, and a 1,2-diamino compound, such as o-phenylenediamine (Scheme 
2). First, the o-quinone was prepared by oxidation of 4-methylcatechol with NaIO4, immediately followed by 
reaction with o-phenylenediamine, giving rise to 2-methylphenazine, which was then transformed into 2-
bromomethylphenazine using standard NBS bromination conditions (Experimental section).  
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Ligands 1-3 were prepared by reacting the corresponding halogen derivative with three-fold excess of 1,2-
bis(4-pyridyl)ethane for 24 h in acetone at room temperature, with yields ranging from 74 to 80%. Afterward, 
complexes 4-6 were obtained by reaction of the corresponding ligand with a solution of 
ethylenediaminedichloroplatinum(II) in refluxing water for 6 h. After purification by column chromatography, a 
subsequent treatment of the complexes in water with ammonium hexafluorophosphate (NH4PF6) was required to 
precipitate the complexes, and to remove the NH4Cl salt employed in the purification step. A second ion-
exchange step was carried out to afford the final, water-soluble products, as the bromide salts to be used in DNA 
interaction studies. 
 
Scheme 1. Target compounds (1-6). Reagents and conditions: 1,2-bis(4-pyridyl)ethane, ArCH2X, r.t., 24 h, 
acetone, 74-78%; PtCl2(en)2, water, reflux, 6 h, 22-61%. 
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Scheme 2. Preparation of 2-bromomethylphenazine. Reagents and conditions: NaIO4, H2O, r.t.; CH3COOH, 
reflux, 4 h, 24% (2 steps); NBS, benzoyl peroxide, CCl4, reflux, 72 h, 53%. 
 
 
2.2. DNA interaction 
 
2.2.1.Viscometric measurements 
After the synthesis of compounds 1-6, our next goal was to obtain direct evidence of DNA interaction and, 
specifically, we wanted to discern between DNA intercalation and groove binding modes. It is well established 
that viscosity measurements provide a simple way for determining the binding modes of DNA ligands.
14 
When a 
DNA intercalant inserts itself between adjacent base pairs within duplex DNA, the helix must unwind to create a 
gap to accommodate the incoming ligand. This unwinding process increases the overall contour length of the 
helix and, as a result, the DNA solution becomes more viscous. Because groove binding compounds do not 
require insertion between the base pairs, DNA lengthening does not occur, and in these circumstances viscosity is 
not significantly altered. Thus, viscometric experiments can be readily employed to distinguish between different 
non-covalent DNA binding modes. According to the theory of Cohen and Eisenberg,
15
 from gradual titration of 
DNA solutions with the compounds of interest, linear plots of the cubed root of the relative DNA viscosity 
( / o)
1/3
 versus the molar ratio of bound ligand to DNA nucleotide (r) can be easily obtained. The slopes values 
in these plots correlate well with the DNA-ligand binding modes. Thus, groove binding compounds usually 
display a slope close to 0.0, whereas classical monointercalants result in a slope close to 1.0.
15
 In the case of 
bisintercalation, a slope of approximately twice that the one observed for a monointercalant is usually expected.
3
 
In practice, slope values reported in the literature typically lie in the range 0.8-1.5 for DNA monointercalants
16
 
and 1.3-2.3 for DNA bisintercalants.
16c,17
 
Viscometric measurements were carried out at 25 ± 0.01 °C by adding aliquots of compounds 1-6 to the DNA 
solutions of CT DNA, in 10 mM sodium phosphate buffer (pH = 7.2). Flow times were recorded in the presence 
(  and in the absence ( ) of dye. Concentrations of DNA were kept constant in experiments with compounds 1-
3, and slightly variable (with the percentage of dilution kept below 5%) in the case of compounds 4-6, because 
the platinum(II) complexes were found to precipitate at relatively high concentrations, if previously mixed with 
DNA. Parallel experiments performed with ligands 1-3 under slightly variable DNA concentration did not show 
significant differences in the slope values obtained, in comparison to experiments at constant DNA 
concentration. The viscosity data for compounds 1-6 were plotted as ( )
1/3
 versus r, as shown in Figure 1. 
The tested compounds demonstrated a linear ( )
1/3
 versus r correlation in the typical r range used in these 
experiments, with the exception of compound 4, the naphthalene platinum(II) complex, for which no linearity 
was observed at r values ≥ 0.05. In the case of the ligands 1-3, the slopes obtained from viscosity plots were 0.31 
± 0.04, 0.84 ± 0.03, and 0.65 ± 0.02, respectively. Clearly, compounds 1 and 3 both interact with CT DNA with a 
mixed binding mode groove binding and intercalation, with a more significant contribution of intercalation for 
compound 3. In the case of compound 2, containing the anthracene chromophore, the results point towards a 
monointercalative DNA binding mode.  
For platinum(II) complexes 4-6, the slopes obtained from viscosity plots were 0.88 ± 0.06, 1.85 ± 0.11, and 
1.59 ± 0.02, respectively. In this case, it is evident that compounds 5 and 6 both interact with CT DNA as 
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bifunctional intercalants, unlike compound 4, which behavior suggests that it binds DNA through 
monointercalation. 
 
Figure 1. Viscometric measurement experiments of calf thymus DNA and compounds 1-6 at 25 ºC (10 mM 
sodium phosphate buffer, pH = 7.2). Assays were performed at least in duplicate. The averaged slopes are: (1) 
0.31 ± 0.04, (2) 0.84 ± 0.03, (3) 0.65 ± 0.02, (4) 0.88 ± 0.06, (5) 1.85 ± 0.11 and (6) 1.59 ± 0.02. 
 
2.2.1. Competition dialysis 
After the establishment of the DNA binding mode for the synthesized compounds, we were interested in 
investigating whether the studied compounds bind DNA with sequence selectivity. To this end, we employed 
competition equilibrium dialysis, a technique developed by the Chaires group
18-20
 that allows a relative fast 
screening of multiple DNA structures binding to small-molecule ligands. The method also allows the 
determination of apparent binding constants. It is based on the fundamental thermodynamic principle of 
equilibrium dialysis
21
 and, in particular, it represents an extension of the Crothers competition dialysis method.
22
  
The results obtained for compounds 2, 3, 5 and 6 (naphthalene derivatives were not included in the 
experiments, due to overlap of their UV absorption spectra at DNA absorption maximum) are depicted in Figure 
2. It represents a bar graph showing the ligand concentrations bound to Calf thymus (CT) DNA and to 
Clostridium perfringens (CP) DNA and to the synthetic, double-helical polynucleotides [poly(dGdC)]2 and 
[poly(dAdT)]2. The results were obtained following the protocol described by Chaires, with some minor 
modifications: 2.5 M solutions of ligands 2, 3, 5 and 6 (in the dialysate solution) were equilibrated with 75 M 
bp of nucleic acid (in each sample dialysis unit) for 24 h. At the end of the equilibration period, sodium dodecyl 
sulfate (SDS) was added to the dialysis solutions, and UV-visible spectra were recorded in order to determine the 
concentrations of free and DNA-bound ligands. The amount of the DNA-bound ligand was averaged over three 
trials. The competition dialysis data were then used to calculate the apparent association constants of ligands 2, 3, 
5 and 6, given by the equation Kapp = Cb /(Cf)(Stotal-Cb),
20
 where Cb is the amount of ligand bound, Cf is the free 
ligand concentration and Stotal = 75 M bp (Table 1).  
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Figure 2. The bar graphs indicate the concentrations of bound ligands 2 (light blue), 3 (orange), 5 (dark blue) and 
6 (brown) detected after a 24 h equilibration in competition binding dialysis studies of four DNA sequences. The 
abbreviations CT DNA, and CP DNA correspond to Calf thymus, and Clostridium perfringens DNA, 
respectively. 
 
Table 1. Apparent association constants obtained by competition dialysis  
     
 Compound 2  Compound 3 Compound 5 Compound 6 
     
     
DNA Kapp 10
-5
 M
-1
 Kapp 10
-5
 M
-1
 Kapp 10
-5
 M
-1
 Kapp 10
-5
 M
-1
 
     
     
CT DNA   (42% GC) 0.61 ± 0.08 0.20 ± 0.02 2.68 ± 0.14 1.03 ± 0.07 
CP DNA   (31% GC) 0.50 ± 0.03 0.17 ± 0.01 1.31 ± 0.07  1.22 ± 0.07 
[poly(dGdC)]2   (100% GC) 0.55 ± 0.05 0.27 ± 0.08 1.00 ± 0.02  1.69 ± 0.04 
[poly(dAdT)]2   (0% GC) 0.24 ± 0.02 0.41 ± 0.06 0.38 ± 0.05 1.22 ± 0.12 
     
 
Figure 2 and Table 1 show that, for all DNA sequences studied, compounds 2 and 3 have less affinity for 
DNA than the corresponding platinum(II) complexes and, in the case of the phenazine derivatives (compounds 3 
and 6) this difference is more pronounced (about a 5-fold increase in DNA affinity for the metal complex). 
However, the increase in affinity between the parent ligands and the platinum(II) complexes is modest, and it 
does not correspond to the expected one considering the difference between monointercalative and 
bisintercalative mechanisms, and the existence of certain cooperativity in DNA binding. This seems to indicate 
that the presence of the ethylenediamine platinum(II) moiety may have a significant effect, such as conditioning 
the binding geometry of the semi-rigid 1,2-bis(4-pyridyl)ethane linkers along the DNA grooves.  
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Regarding selectivity, nor the ligand or the platinum(II) complex of the phenazine derivatives exhibited a clear 
preference to bind the GC- or AT-rich DNA sequences, whereas the anthracene compound 2 did demonstrate a 
slight preference to bind GC DNA sequences, which was notably accentuated in the case of the platinum(II) 
complex, compound 5. This compound clearly shows a preference for GC base pairs, as exemplified by an 
increase in levels of binding to CT DNA (42% GC, Kapp = 2.68 10
5
 M
-1
) relative to CP DNA (31% GC; Kapp = 
1.31 10
5
 M
-1
) and to [poly(dGdC)]2 (Kapp = 1.00 10
5
 M
-1
) relative to [poly(dAdT)]2 (Kapp = 0.38 10
5
 M
-1
).  
 
3. Conclusions  
 
In summary, we have reported the synthesis of a family of compounds based on ethylenediamine platinum(II) 
complexes connected through semi-rigid chains of 1,2-bis(4-pyridyl)ethane to DNA intercalating subunits 
(naphthalene, anthracene or phenazine). The synthetic procedures described herein allow an easy and efficient 
preparation of these multifunctional compounds in acceptable yields. Moreover, the interactions of the parent 
ligands and their platinum(II) complexes with DNA have been studied by viscometric titrations and competition 
equilibrium dialysis assays. Anthracene and phenazine derivatives have proven, in general, to be more 
efficacious than the naphthalene compounds as DNA intercalating agents, which was expected based on their 
increased planar aromatic surface. However, a significant difference in DNA binding between the phenazine and 
anthracene metal complexes has been observed where, despite the subtle structural difference among these 
compounds (replacement of the nitrogens atoms at 9,10 positions of the aromatic ring for carbon atoms), there is 
a considerable increase in DNA sequence selectivity in the anthracene-containing compound. As a general trend, 
the parent ligands show monointercalative modes of DNA interaction, especially in the case of the anthracene 
derivative, whereas the platinum(II) complexes recognize DNA via bisintercalative interactions.  
Regarding the potential applications of these molecules, the platinum(II) complexes described in this article 
may serve as useful probes for the study of ligand-DNA interactions, and they may constitute starting points for 
the development of novel compounds with potential therapeutic use, incorporating other aromatic systems or 
labile ligands coordinated to the platinum(II) center. These compounds could also be studied, for example, as 
feasible DNA photocleaving agents, in particular the anthracene platinum(II) complex, compound 5. Indeed, we 
have previously reported that certain platinum(II) complexes linked to anthracene derivatives can cleave plasmid 
DNA very efficiently under physiological conditions at nanomolar concentrations.
23
 In addition, the compounds 
could be used as scaffold structures to create second-generation compounds that can recognize other DNA 
secondary structures of biological relevance besides duplex DNA. These may include, for example, triplex and 
quadruplex DNA structures, which are extremely interesting in cancer chemotherapy, e.g. antisense technology, 
oncogene expression modulating agents, telomerase inhibitors, etc.  
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4. Experimental 
 
Melting points were determined using an Electrothermal Digital IA9100 apparatus. 
1
H and 
13
C NMR spectra 
were recorded on either Varian Unity or Varian Mercury-VX (300 MHz) or Varian Inova (500 MHz) 
spectrometers. Carbon and proton assignments were based on HSQC and HMBC experiments. Infrared spectra 
were acquired with an FT-IR Perkin Elmer Spectrum 2000 spectrophotometer. Elemental analyses were done on 
a Leco CHNS-932 automatic analyzer. ESI mass spectra were recorded on a Thermo Scientific TSQ Quantum 
LC/MS or an Agilent 6210 LC/MS/TOF instruments. FAB mass spectra were obtained on a V.G. AutoSpec 
spectrometer with 3-nitrobenzyl alcohol as matrix. UV-visible spectra were recorded on a Lambda 18 Perkin-
Elmer spectrometer. Merck silica gel 60 (230-400 ASTM mesh) was employed for flash column 
chromatography. TLC was performed on precoated aluminum silica gel plates (Merck or Macherey-Nagel 60 
F254 0.25 mm). Distilled, deionized water was utilized in the preparation of all buffers and all aqueous reactions. 
Chemicals were of the highest available purity and were used without further purification. Sodium phosphate 
dibasic, and sodium phosphate monobasic were obtained from the Aldrich Chemical Company. The 
concentration of CT DNA solutions was determined by UV-visible spectrophotometry using the extinction 
coefficient 260 = 12,824 M
-1
 (bp) cm
-1
. 
 
Synthesis of 2-methylphenazine. 4-Methylcatechol (3.72 g, 30 mmol) was dissolved in water (300 mL) at room 
temperature and sodium periodate (6.37 g, 31.4 mmol) was added. The mixture was stirred vigorously for 1 min 
before extraction with methylene chloride (2 × 70 mL). The organic extract was immediately added to a solution 
of o-phenylenediamine (3.24 g, 30 mmol) in methylene chloride (40 mL) with stirring. Then glacial acetic acid 
(20 mL) was added dropwise over a period of 10 minutes and the solution was left to stir for 30 minutes at room 
temperature before being heated to reflux for 4 h. The solution was cooled and washed successively with water 
(100 mL), aqueous sodium hydrogen carbonate (2 × 100 mL) and finally brine (100 mL). The organic layer was 
dried and evaporated to dryness giving a brown solid. Filtration through a plug of alumina using methylene 
chloride afforded an orange solid, which was purified by flash chromatography through silica gel (5:1 
hexane/ethyl acetate, Rf = 0.3) affording the title compound (1.4 g, 24%) as a yellow solid, mp 117-119 °C (lit.
13
 
117 °C); 
1
H NMR (300 MHz, CDCl3): δ (ppm) 2.66 (3H, s, CH3), 7.70 (1H, dd, J 9.2, 1.8 Hz, H-3), 7.80–7.91 
(2H, m, H-7, H-8), 8.06 (1H, brs, H-1), 8.17 (1H, d, J 9.2 Hz, H-4), 8.25–8.32 (2H, m, H-6, H-9). HRMS (ESI-
TOF): m/z found 195.0925 (M+H)
+
, C13H11N2 requires 195.0922. 
Synthesis of 2-bromomethylphenazine. 2-Methylphenazine (200 mg, 1 mmol) was dissolved in carbon 
tetrachloride (10 mL) at room temperature. Freshly recrystallized N-bromosuccinimide (NBS) (196 mg) was 
added, followed by benzoyl peroxide (8 mg) and the reaction mixture was gentle refluxed for 71 hours. Then it 
was cooled at room temperature, filtered, and the filtrate washed successively with water (10 mL) and brine (10 
mL). The organic extract was dried, evaporated and dried overnight in a desiccator to give the crude product, 
which was purified by flash chromatography (5:1 hexane: ethyl acetate, Rf = 0.23) to give the title compound as a 
yellow product (149 mg, 53%), m.p. 157-159 °C (lit.
13
 156-162 °C); 
1
H NMR (300 MHz, CDCl3): δ (ppm) 4.74 
(2H, s, CH2Br), 7.84–7.88 (3H, m, ArH), 8.21–8.26 (4H, m, ArH); HRMS (ESI-TOF): m/z found 273.0035 
(M+H)
+
, C13H10BrN2 requires 273.0027. 
1-(Naphthalen-2-ylmethyl)-4-(2-(pyridin-4-yl)ethyl)pyridinium bromide (1). To a solution of 1,2-bis(4-
pyridyl)ethane (200 mg, 1.08 mmol) in dry acetone (2 mL) a solution of 2-bromomethylnaphtalene (83 mg, 0.36 
mmol) in dry acetone (2 mL) was added dropwise. The reaction mixture was stirred under argon at room 
temperature for 24 h and then cooled at 0 °C. The solid was filtered, washed with cold acetone and dried 
affording pure product 1 (108 mg, 74%); mp 189-191 °C; [Found: C, 68.18; H, 5.39; N, 7.15. C23H21BrN2 
requires C, 68.15; H, 5.22; N, 6.91%]; IR (KBr):  3017, 2980, 1639, 1603, 1518, 1510, 1472, 1413, 1151 cm
-1
; 
1
H-NMR (DMSO-d6, 500 MHz)  (ppm): 3.05 (2H, t, J 8.1 Hz, CH2CH2), 3.2 (2H, t, J 8.1 Hz, CH2CH2), 5.95 
(2H, s, Py
+
CH2Naph), 7.27 (2H, d, J 5.9 Hz, H Py), 7.55–7.59 (3H, m, H-3, H-6, H-7 Naph), 7.91–7.95 (2H, m, 
H-5, H-8 Naph), 7.98 (1H, d, J 8.5 Hz, H-4 Naph), 8.04 (1H, brs, H-1 Naph), 8.07 (2H, d, J 6.5 Hz, H Py
+
), 8.44 
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(2H, d, J 5.9 Hz, H Py), 9.13 (2H, d, J 6.5 Hz, H Py
+
); 
13
C-NMR (DMSO-d6, 75 MHz)  (ppm): 33.7, 34.9, 62.9, 
124.1, 125.8, 127.1, 127.3, 127.9, 128.2, 128.3, 128.5, 129.2, 132.1, 132.8, 133.1, 144.4, 149.1, 149.8, 161.8.  
1-(Anthracen-9-ylmethyl)-4-(2-(pyridin-4-yl)ethyl)pyridinium chloride (2). To a solution of 1,2-bis(4-
pyridyl)ethane (200 mg, 1.08 mmol) in dry acetone (2 mL) a solution of 9-chloromethylanthracene (78 mg, 0.36 
mmol) in dry acetone (2 mL) was added dropwise. The reaction mixture was stirred at room temperature for 24 
h. The solid was filtered, washed with cold acetone and dried at 50 °C affording pure product 2 (114 mg, 77%); 
mp 224-226 °C; [Found: C, 79.15; H, 5.72; N, 6.50. C27H23ClN2 requires C, 78.91; H, 5.64; N, 6.82%]; IR (KBr): 
 3015, 1633, 1602, 1515, 1467, 1419, 1143 cm
-1
; 
1
H-NMR (DMSO-d6, 300 MHz)  (ppm): 2.97 (2H, t, J 8.1 
Hz, CH2CH2), 3.20 (2H, t, J 8.1 Hz, CH2CH2), 6.89 (s, 2H, Py
+
CH2Anthr), 7.23 (2H, d, J 6.3 Hz, H Py), 7.60–
7.70 (4H, m, H-2, H-3, H-6, H-7 Anthr), 7.93 (2H, d, J 6.9 Hz, H Py
+
), 8.25 (2H, d, J 8.2 Hz, H-4, H-5 Anthr), 
8.34 (2H, d, J 8.9 Hz, H-1, H-8 Anthr), 8.42 (2H, d, J 6.3 Hz, H Py), 8.75 (2H, d, J 6.9 Hz, H Py
+
), 8.91 (1H, s, 
H-10 Anthr). 
13
C-NMR (DMSO-d6, 75 MHz)  (ppm): 33.6, 34.7, 55.3, 122.4, 123.4, 124.1, 125.9, 128.2, 128.4, 
129.7, 131.2, 131.3, 131.5, 143.5, 149.1, 149.6, 161.5.  
1-(Phenazin-2-ylmethyl)-4-(2-(pyridin-4-yl)ethyl)pyridinium bromide (3). To a solution of 1,2-bis(4-
pyridyl)ethane (200 mg, 1.08 mmol) in dry acetone (2 mL) a solution of 2-bromethylphenazine (100 mg, 0.36 
mmol) in dry acetone (10 mL) was added dropwise. The reaction mixture was stirred at room temperature for 28 
h and then the solid was filtered, washed with cold acetone and dried at 50 °C affording pure product 3 (128 mg, 
78%); mp 273-275 °C; [Found: C, 65.52; H, 4.71; N, 12.43. C25H21BrN4 requires C, 65.65; H, 4.63; N, 12.25%]; 
IR (KBr):  3052, 1645, 1605, 1513, 1475, 1176, 1153 cm
-1
; 
1
H-NMR (DMSO-d6, 300 MHz)  (ppm): 3.05 (2H, 
t, J 7.8 Hz, CH2CH2), 3.27 (2H, t, J 7.8 Hz, CH2CH2), 6.13 (2H, s, Py
+
CH2Phenazine), 7.28 (2H, d, J 6.0 Hz, 
H Py), 7.98–8.03 (3H, m, H-3, H-7, H-8 Phenazine), 8.12 (2H, d, J 6.7 Hz, H Py+), 8.25 8.29 (3H, m, H-1, H-6, 
H-9 Phenazine), 8.33 (1H, d, J 9.1 Hz, H-4 Phenazine), 8.46 (2H, d, J 6.0 Hz, H Py), 9.21 (2H, d, J 6.7 Hz, 
H Py
+
). 
13
C-NMR (DMSO-d6, 75 MHz)  (ppm): 33.7, 35.0, 62.5, 124.2, 128.5, 129.3, 129.5, 129.6, 130.6, 
130.7, 131.9, 137.4, 142.6, 142.7, 143.4, 143.5, 144.8, 149.4, 149.6, 162.2.  
Bis-[4-(2-(1-(naphthalen-2-ylmethyl)pyridinium-4-yl)ethyl)pyridinium-1-yl](1,2-ethylendiamine)platinum(II) 
(tetrakis)hexafluorophosphate (4). A suspension of PtCl2(en)2 (40 mg, 0.12 mmol) in water (10 mL) was heated 
at reflux until to obtain a clear solution. Then a solution of 1 (100 mg, 0.24 mmol) in methanol-water (1:10) (3 
mL) was added. The reaction mixture was heated at reflux for 6 h. The solid was filtered and the filtrate 
concentrated under reduced pressure affording a colorless oil. The crude product was purified by column 
chromatography on silica gel and methanol-374 mM aqueous ammonium chloride solution (2:1) as eluent. The 
combined fractions were concentrated at reduced pressure and the residue thus obtained was dissolved in water 
and treated with ammonium hexafluorophosphate. The precipitate was filtered, washed with water and dried in a 
oven at 50 °C yielding 40 mg (22%) of pure product 4; mp 176-178 °C (d). [Found: C, 38.91; H, 3.42; N, 5.26. 
C48H50F24N6P4Pt requires C, 38.80; H, 3.39; N, 5.66%]; IR (KBr):  3419, 1639, 1622, 1438, 1157 cm
-1
. 
1
H-
NMR (D2O, 300 MHz)  (ppm): 2.55 (4H, s, NCH2CH2N), 2.74 (4H, t, J 7.6 Hz, CH2CH2), 2.93(4H, t, J 7.6 Hz, 
CH2CH2), 5.67 (4H, s, Py
+
CH2Naph), 6.96 (4H, d, J 6.5 Hz, H Py), 7.14 (2H, dd, J 8.5, 1.8 Hz, H-3 Naph), 7.30–
7.38 (4H, m, H-6, H-7 Naph), 7.51 (4H, d, J 6.7 Hz, H Py
+
), 7.60–7.71 (8H, m, H-1, H-4, H-5, H-8 Naph), 8.11 
(4H, d, J 6.5 Hz, H Py), 8.51 (4H, d, J 6.7 Hz, H Py
+
); 
13
C-NMR (DMSO-d6, 75 MHz)  (ppm) 33.4, 34.3, 63.1, 
125.7, 126.9, 127.1, 127.3, 127.8, 128.1, 128.4, 129.2, 131.9, 132.8, 133.0, 144.5, 152.1, 154.5, 161.2; LRMS 
(ESI) m/z found 1340 (M
+
PF6), C48H50F18N6P3Pt requires 1340.26.  
Bis-[4-(2-(1-(anthracen-9-ylmethyl)pyridinium-4-yl)ethyl)pyridinium-1-yl](1,2-ethylendiamine)platinum(II) 
(tetrakis)hexafluorophosphate (5). A suspension of PtCl2(en)2 (40 mg, 0.12 mmol) in water (10 mL) was heated 
at reflux until to obtain a clear solution. Then a solution of 2 (100 mg, 0.24 mmol) in water (2 mL) was added. 
The reaction mixture was heated at reflux for 6 h. The solid was filtered and the filtrate evaporated under reduced 
pressure. The crude product was purified by column chromatography on silica gel and methanol-374 mM 
aqueous ammonium chloride solution (2:1) as eluent. The combined fractions were concentrated at reduced 
pressure and the residue dissolved in water and treated with ammonium hexafluorophosphate. The yellow 
precipitate was filtered, washed with water and dried in an oven at 80 °C affording 46 mg (24%) of pure product 
5; mp 245-248 °C (d); [Found: C, 42.51; H, 3.39; N, 5.17. C56H54F24N6P4Pt requires C, 42.41; H, 3.43; N, 5.30]; 
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IR (KBr):  3424, 1640, 1624, 1467, 1450, 1438, 1142 cm
-1
. 
1
H-NMR (DMSO-d6, 300 MHz)  (ppm): 2.55 (4H, 
s, NCH2CH2N), 2.90 (8H, m, CH2CH2), 6.30 (4H, brs, NH2), 6.89 (4H, s, Py
+
CH2Anthr), 7.52 (4H, d, J 6.4 Hz, 
H Py), 7.59–7.71 (8H, m, H-2, H-3, H-6, H-7 Anthr), 7.93 (4H, d, J 6.4 Hz, H Py+), 8.25 (4H, d, J 8.0 Hz, H-4, 
H-5 Anthr), 8.37 (4H, d, J 8.9 Hz, H-1, H-8 Anthr), 8.61 (4H, d, J 6.4 Hz, H Py), 8.77 (4H, d, J 6.4 Hz, H Py
+
), 
8.92 (2H, s, H-10 Anthr); 
13
C-NMR (DMSO-d6, 75 MHz)  (ppm): 33.4, 34.3, 47.6, 55.5, 119.6, 122.2, 123.3, 
126.0, 127.0, 128.1, 128.5, 129.8, 131.3, 131.5, 143.6, 152.1, 154.4, 161.1; FAB-MS (m-NBA) m/z found 1440.3 
(M
+
PF6), C56H54F18N6P3Pt requires 1440.29.  
Bis-[4-(2-(1-(phenazin-2-ylmethyl)pyridinium-4-yl)ethyl)pyridinium-1-yl](1,2-ethylendiamine)platinum(II) 
(tetrakis)hexafluorophosphate (6). A suspension of PtCl2(en)2 (28 mg, 0.086 mmol) in water (7 mL) was heated 
at reflux until to obtain a clear solution. Then a solution of 3 (80 mg, 0.17 mmol) in water (2 mL) was added. The 
reaction mixture was heated at reflux for 6 h. The solid was filtered and the filtrate concentrated under reduced 
pressure. The crude product was purified by column chromatography on silica gel and methanol-2.8 M aqueous 
ammonium chloride solution (2:1) as eluent. The combined fractions were concentrated at reduced pressure and 
the residue dissolved in water and treated with ammonium hexafluorophosphate. The yellow precipitate was 
filtered, washed with water and dried in a oven at 80 °C affording 85 mg (61%) of pure product 6; mp 213-215 
°C (d); [Found: C, 39.44; H, 3.06; N, 9.04. C52H50F24N10P4Pt requires C, 39.28; H, 3.17; N, 8.81%]; IR (KBr):  
3430, 1644, 1624, 1516, 1473, 1438 cm
-1
.
1
H-NMR (DMSO-d6, 300 MHz)  (ppm): 2.56 (4H, s, NCH2CH2N), 
3.0–3.27 (8H, m, CH2CH2), 6.14 (4H, s, Py
+
CH2Phenazine), 6.20 (4H, brs, NH2) 7.58 (d, 4H, J 6.0 Hz, H Py), 
7.98–8.04 (m, 6H, H-3, H-7, H-8 Phenazine), 8.14 (d, 4H, J 6.4 Hz, H Py+), 8.24–8.29 (6H, m, H-1, H-6, H-9 
Phenazine), 8.34 (2H, d, J 8.9 Hz, H-4 Phenazine), 8.65 (4H, d, J 6.0 Hz, H Py), 9.24 (4H, d, J 6.4 Hz, H Py
+
); 
13
C-NMR (DMSO-d6, 75 MHz)  (ppm): 33.5, 34.5, 47.7, 62.6, 127.0, 128.4, 129.2, 129.5, 129.6, 130.7, 130.8, 
131.9, 137.4, 142.5, 142.7, 143.4, 143.5, 144.9, 152.2, 154.6, 161.7. FAB-MS (m-NBA) m/z found 1444.3 
(M
+
PF6). HRMS (ESI-TOF): m/z found 1444.2781 (M
+–PF6), C52H50F18N10P3Pt requires 1444.2793.  
Anion exchange from hexafluorophosphate to bromide. The hexafluorophosphate salt was dissolved in 
nitromethane. By addition of a nitromethane solution of tetraethylammonium bromide, the bromide salt 
precipitates. The filtered precipitate was washed with nitromethane and then with cold acetone. 
 
4.3 Viscometric titrations 
 
The viscometric measurements were performed in a Visco System AVS 470 at 25 ± 0.01 ºC, using a 
microUbbelohde (K = 0.01) capillary viscometer. Solutions of DNA (Calf thymus, CT), ligands and platinum 
complexes were prepared in sodium phosphate buffer (10 mM, pH = 7.2). DNA solutions (0.35–0.40 mM, in 
nucleotides) were equilibrated for 20 minutes at 25.00 ºC and then 20 flow times were registered. Small aliquots 
(30–60 L) of solutions of compounds 1-3 (0.4–1.5 mM) were added next maintaining the DNA concentration 
constant. For platinum complexes, compounds 4-6, small aliquots of solutions (0.6–1.6 mM) were added without 
maintaining constant the DNA concentration, with a maximum dilution of 5%. Before each flow time 
registration, the solutions were equilibrated for at least 20 minutes at 25 ± 0.01 °C and then 20 flow times were 
measured. With the averaged flow times and the viscometer constant, the viscosities ( ) for each point were 
calculated, with representing the DNA solution viscosity in the absence of compound. The viscosity results 
were then plotted as (
1/3
 versus the molar ratio of bound ligand to DNA nt (r).   
 
4.4 Equilibrium dialysis 
 
Competition Dialysis Assay. Calf thymus (CT), Clostridium perfringens (CP) DNAs and the synthetic 
polynucleotides [poly(dGdC)]2 and [poly(dAdT)]2 were purchased from Sigma and were used without further 
purification. A 10 mM sodium phosphate buffer (pH = 7.2) was utilized in the preparation of all nucleic acid 
stock solutions. The concentrations of the nucleic acid solutions were determined by UV-visible 
spectrophotometry using the max values and extinction coefficients listed in Table S1 (Supplementary data). 
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Extinction coefficients for compounds 2, 3, 5 and 6 were determined in 10 mM sodium phosphate buffer pH = 
7.0 in the absence and in the presence of 1% SDS (w/v) or excess of CT DNA (Table S2, supplementary data). 
Competition dialysis experiments were performed following a similar protocol as the one described by Chaires.
18-
20
 For each dialysis assay, a 0.5 mL volume of DNA (75 M bp DNA in buffer; Table S1) was pipetted into one 
of 4 individual Spectra/Por DispoDialyzer units (S135062, Spectrum Laboratories, Inc.). The 4 dialysis units 
were then placed in a beaker containing 225 mL of a 2.5 M solution of 2, 3 and 5, 6 in buffer. The beaker was 
covered with Parafilm and wrapped in foil, and its contents were allowed to equilibrate with continuous stirring 
for 24 h at room temperature (20-22 ºC). At the end of the equilibration period, the DNA solutions inside the 
dialysis units were carefully transferred to microcentrifuge tubes and a 10.0% (w/v) stock solution of sodium 
dodecyl sulfate (SDS) was added to give a final concentration of 1.0% (w/v). The DNA-SDS solutions were 
allowed to equilibrate for 2 h, after which the total concentration of the corresponding ligand 2, 3 and 5, 6 (Ct) 
was determined by UV-visible absorbance measurements using the extinction coefficient for free ligands in the 
presence of 1.0% SDS. An appropriate correction for the slight dilution of the sample resulting from the addition 
of SDS stock solution was made. The concentration of free ligands 2, 3 and free complexes 5, 6 (Cf) was also 
determined spectrophotometrically using an aliquot of their dialysate solution. The amount of DNA-bound 2, 3, 5 
and 6 (Cb) was then calculated by difference (Cb = Ct - Cf). 
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Supplementary Material 
Supplementary data (Table S1 and Table S2) associated with this article, can be found, in the online version, at 
http://dx.doi.org/. 
 
 
 
Table S1. Nucleic Acid Samples Used in Competition 
Dialysis Experiments
a
  
   
   
Deoxyribonucleic acid (nm) (M
-1 
(bp)cm
-1
) 
   
   
CT DNA (42% GC) 260 12,824 
CP DNA (31% GC) 260 12,476 
[poly(dGdC)]2 (100% GC) 254 16,800 
[poly(dAdT)]2 (0% GC) 262 13,200 
   
a
  is the molar extinction coefficient at the 
wavelength , expressed in terms of DNA base pairs. 
 
 
Table S2. Wavelengths and Extinction Coefficients 
in 10 mM sodium phosphate buffer (pH = 7.2)  
     
     
Compound (nm) (M
-1
cm
-1
) SDS (M
-1
cm
-1
) bound (M
-1
cm
-1
) 
     
     
1 225 74,234 – – 
2 371 7,284 7,130 ( 373) 3,500 ( 379) 
3 371 13,442 13,211 ( 367) 8,463 ( 374) 
4 225 133,533 – – 
5 372 10,967 11,989 ( 373) 5,327 ( 379) 
6 371 21,423 21,737 ( 373) 14,936 ( 373) 
     
 
 
